Table 1.
Demographic and clinical characteristics at study enrolment of 522 patients on HAART, Bangalore, India (2007–2011): n (%)
| Variables | All (n=522) | Men (n=353) | Women (n=168) | p a |
|---|---|---|---|---|
| Gender | ||||
| Male | 353 (67.6) | |||
| Female | 168 (32.2) | |||
| Transgenderb | 1 (0.2) | |||
| Patient age: mean (SD) | 37.5 (8.5) | 39.0 (8.2) | 34.3 (8.2) | <0.001 |
| Care setting | 0.005 | |||
| Public | 279 (53.5) | 198 (56.1) | 81 (48.2) | |
| Private | 91 (17.4) | 68 (19.3) | 23 (13.7) | |
| Public-private | 152 (29.1) | 87 (24.6) | 64 (38.1) | |
| HAART regimen | 0.106 | |||
| 3TC +D4T+NVP | 180 (34.5) | 114 (32.3) | 65 (38.7) | |
| 3TC+AZT+NVP | 261 (50.0) | 180 (51.0) | 81 (48.2) | |
| Other NVP based | 3 (0.6) | 1 (0.3) | 2 (1.2) | |
| 3TC+D4T+EFV | 31 (5.9) | 20 (5.7) | 11 (6.5) | |
| 3TC+AZT+EFV | 40 (7.7) | 33 (9.3) | 7 (4.2) | |
| TDF+FTC+EFV | 6 (1.1) | 5 (1.4) | 1 (0.6) | |
| Protease inhibitors | 1 (0.2) | 0 (0.0) | 1 (0.6) | |
| Median (IQR) CD4 cells/µl | 333 (210–470) | 315 (195–434) | 362 (243–509) | 0.004 |
| Median (IQR) duration on HAART, in months | 17 (6–30) | 18 (7–30) | 16 (4–31) | 0.433 |
SD, standard deviation; IQR, interquartile range.
a
Based on t-test for age, exact χ 2-test for care setting and regimen, and Mann-Whitney U-test for CD4 and duration on HAART.
b
Excluded from analyses by gender.